All animals were given 3 log-10 pfu of MP-12 vaccine intramuscularly at DPV 84 as a surrogate challenge for RVFV, and the anamnestic immune response determined by PRNT-80 titers thereafter on the days shown. This demonstrated that animals pre-vaccinated with either MP-122 or the deletion variant MP-121-NSm-del exhibited an enhanced response indicative of priming for the response by the initial vaccination. Access data in file Antibody_results_intramuscular.xlsx

The overall purpose of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture is to increase the food supply by developing and applying a vaccine for the prevention of Rift Valley fever disease among livestock in Africa. Rift Valley Fever (RVF) is a mosquito-borne viral disease that continues to have a devastating impact on human and animal health in Africa. Since the discovery of RVF as the cause of an outbreak among sheep and humans during the early 1930s in the Rift Valley in Kenya, the disease has emerged as one of the most important zoonoses in Africa. The disease has and continues to affect the health of thousands to millions of humans and animals, and the livestock industry has lost millions of dollars, and therefore, affecting hundreds of millions of those whose livelihood depends on livestock, exaggerating poverty on already deprived communities.

The specific aim of the Lab is to conduct a 5 year research project to develop and evaluate a vaccine for the prevention of Rift Valley fever (RVF) among livestock in Tanzania and other RVF virus enzootic African regions and thereby improve food security, nutrition and livelihoods in Africa as a USAID priority under Feed the Future, the U.S. Government’s global hunger and food security initiative. This data asset reports the results of this work.